Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19 + acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.

Original languageEnglish (US)
Pages (from-to)45-63
Number of pages19
JournalNature Reviews Clinical Oncology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Antigen Receptors
Cell- and Tissue-Based Therapy
Guidelines
Pediatrics
Acute Lung Injury
Hematopoietic Stem Cell Transplantation
Autoantigens
Child Care
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genetic Therapy
Immunotherapy
Young Adult
Sepsis
Research Personnel
Delivery of Health Care
T-Lymphocytes
Research
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. / the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network.

In: Nature Reviews Clinical Oncology, Vol. 16, No. 1, 01.01.2019, p. 45-63.

Research output: Contribution to journalReview article

the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network 2019, 'Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy', Nature Reviews Clinical Oncology, vol. 16, no. 1, pp. 45-63. https://doi.org/10.1038/s41571-018-0075-2
the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. / Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. In: Nature Reviews Clinical Oncology. 2019 ; Vol. 16, No. 1. pp. 45-63.
@article{fc4d91c66da54ce6994ab65699c9ac22,
title = "Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy",
abstract = "In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19 + acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.",
author = "{the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network} and Mahadeo, {Kris M.} and Khazal, {Sajad J.} and Hisham Abdel-Azim and Fitzgerald, {Julie C.} and Agne Taraseviciute and Bollard, {Catherine M.} and Priti Tewari and Christine Duncan and Chani Traube and David McCall and Steiner, {Marie E.} and Cheifetz, {Ira M.} and Lehmann, {Leslie E.} and Rodrigo Mejia and Slopis, {John M.} and Rajinder Bajwa and Partow Kebriaei and Martin, {Paul L.} and Jerelyn Moffet and Jennifer McArthur and Demetrios Petropoulos and {O’Hanlon Curry}, Joan and Sarah Featherston and Jessica Foglesong and Basirat Shoberu and Alison Gulbis and Mireles, {Maria E.} and Lisa Hafemeister and Cathy Nguyen and Neena Kapoor and Katayoun Rezvani and Neelapu, {Sattva S.} and Shpall, {Elizabeth J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41571-018-0075-2",
language = "English (US)",
volume = "16",
pages = "45--63",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

AU - the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network

AU - Mahadeo, Kris M.

AU - Khazal, Sajad J.

AU - Abdel-Azim, Hisham

AU - Fitzgerald, Julie C.

AU - Taraseviciute, Agne

AU - Bollard, Catherine M.

AU - Tewari, Priti

AU - Duncan, Christine

AU - Traube, Chani

AU - McCall, David

AU - Steiner, Marie E.

AU - Cheifetz, Ira M.

AU - Lehmann, Leslie E.

AU - Mejia, Rodrigo

AU - Slopis, John M.

AU - Bajwa, Rajinder

AU - Kebriaei, Partow

AU - Martin, Paul L.

AU - Moffet, Jerelyn

AU - McArthur, Jennifer

AU - Petropoulos, Demetrios

AU - O’Hanlon Curry, Joan

AU - Featherston, Sarah

AU - Foglesong, Jessica

AU - Shoberu, Basirat

AU - Gulbis, Alison

AU - Mireles, Maria E.

AU - Hafemeister, Lisa

AU - Nguyen, Cathy

AU - Kapoor, Neena

AU - Rezvani, Katayoun

AU - Neelapu, Sattva S.

AU - Shpall, Elizabeth J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19 + acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.

AB - In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19 + acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.

UR - http://www.scopus.com/inward/record.url?scp=85052923365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052923365&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0075-2

DO - 10.1038/s41571-018-0075-2

M3 - Review article

C2 - 30082906

AN - SCOPUS:85052923365

VL - 16

SP - 45

EP - 63

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 1

ER -